Video Insights
Video Insights
Advertisement
Reuben Ben-David, MDRenal Cell Carcinoma Diagnostics | April 30, 2025
Drs. Ben-David and Joyce evaluate the performance of ctDNA in detecting localized RCC disease recurrence after surgery.
View More
Reuben Ben-David, MDRenal Cell Carcinoma Diagnostics | April 30, 2025
Drs. Ben-David, Joyce share an analysis on recurrence-free survival according to ctDNA status in patients with renal masses.
Alireza Ghoreifi, MDUrothelial Carcinoma | April 30, 2025
Dr. Ghoreifi explains how results suggest feasibility with high rates of pathological downstaging and complete response.
Patrick Gomella, MDNon-Muscle Invasive Urothelial Carcinoma | April 30, 2025
Dr. Gomella and Ambinder provide a comprehensive overview of the growing and changing treatment landscape for NMIBC.
Edwin Posadas, MDLocalized | April 29, 2025
Drs. Posadas and Ambinder reflect on the first AUA guideline update for salvage therapy in prostate cancer in over a decade.
Marc Dall'Era, MDLocalized | April 29, 2025
Dr. Marc Dall'Era spotlights the results from a phase 2 trial on neoadjuvant niraparib for DDR-deficient localized PCa.
Samuel Gold, MDUrothelial Carcinoma | April 28, 2025
Dr. Samuel Gold shares some perspective on the impact of disease recurrence on HRQoL after radical cystectomy.
John Gore, MD, MSUrothelial Carcinoma | April 28, 2025
Dr. John Gore offers interesting data from the CISTO study, favoring radical cystectomy for recurrent high-grade NMIBC.
Joseph Jacob, MD, MCRUrothelial Carcinoma | April 28, 2025
Dr. Joseph Jacob shares the latest 1-year durability and PROs related to TAR-200 for BCG-unresponsive high-risk NMIBC.
Gautam T. Jayram, MDUrothelial Carcinoma | April 29, 2025
Dr. Jayram highlights the updates in the ADVANCED-2 study: TARA-002 for patients with high-grade NMIBC.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | April 15, 2025
Drs. Koshkin and Nizam discuss how a longer treatment-free interval may predict benefit from pembrolizumab rechallenge.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | April 15, 2025
Drs. Koshkin and Nizam break down recent research on pembro in patients with la/mUC who responded to first-course pembro.
Nitin Yerram, MDLocalized | April 14, 2025
Dr. Yerram elucidates the evolving landscape of focal therapy for prostate cancer, emphasizing its ease of adoption.
Nitin Yerram, MDLocalized | April 14, 2025
Dr. Yerram describes his post-HIFU surveillance protocol: regular PSA checks, MRI, and biopsies at defined intervals.
Nitin Yerram, MDLocalized | April 14, 2025
Dr. Yerram explains the use of HIFU and cryotherapy as primary focal therapy modalities, emphasizing a few treatment options.
Nitin Yerram, MDLocalized | April 14, 2025
Dr. Yerram explains how advances in focal therapy technologies over the past decade have driven increased use and acceptance.
Julian Hong, MDProstate Cancer Diagnostics | April 11, 2025
Dr. Hong reviews relevant key findings from clinical trials for oligometastatic disease.
Julian Hong, MDProstate Cancer Diagnostics | April 11, 2025
Dr. Hong reviews the criteria used to determine which patients may benefit from MDT.
Carissa Chu, MDProstate Cancer Diagnostics | April 9, 2025
Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision.
Daniel Joyce, MDRenal Cell Carcinoma Diagnostics | April 16, 2025
CA9 imaging and ZIRCON data offer new insight into managing small renal masses and supporting personalized kidney cancer care
Advertisement
Advertisement